On May 16, 2024, a thematic day dedicated to Modern Health Saving Technologies was held at the RUSSIA EXPO International Exhibition and Forum organized at the National Economy Achievements Exhibition site (VDNKh), where Medsintez Plant presented its products at the joint booth of the Sverdlovsk Region, among the advanced scientific developments and projects of the region. The exhibition was visited by Olga Krivonos, the Deputy Chief of the Russian Federation Government Office, and Mikhail Murashko, the Minister of Health of the Russian Federation. All regions, federal ministries, corporations and public organizations took part in the exhibition, representing the achievements of modern Russia.
"Thanks to the efforts of Evgeny Kuyvashev, the Governor, the Sverdlovsk Region does not stop enhancing its competencies in the production of advanced medical equipment to save people’s lives. Today, some of them are presented at the region’s booth," said Pavel Krekov, Deputy Governor of the Sverdlovsk Region, presenting to the guests the potential of the Middle Urals for the production of high-tech medical equipment and pharmaceutical products.
The Medsintez Plant is one of the key enterprises of the Sverdlovsk Region in the healthcare sector, which is capable of meeting the needs of not only the region, but the entire country for high-quality and affordable drugs. Alexander Petrov, the Chairman of the Board of Directors of the Medsintez Plant, told the distinguished guests of the exhibition about recent scientific developments and future projects of the enterprise. The booth presented the latest recombinant drugs of human albumin, widely used in medicine, follitropin alpha Primapur (FSH) and choriogonadotropin alpha (hCG) for the treatment of infertility, drugs of genetically engineered and analogue human insulin Rosinsulin, as well as a hypoglycemic agent Semaglutide for the treatment of type 2 diabetes mellitus.
Solving the issues of import substitution, the enterprise is developing a full range of hormonal drugs used in a complex of assisted reproductive technologies. The first Russian drug of recombinant human follicle-stimulating hormone Primapur, which is used in the IVF procedure and is included in the list of Vital and Essential Drugs was presented at the exhibition booth by the Medsintez Plant. Primapur is successfully used in clinics throughout Russia, and today more than 20 thousand children have been born with the help of this drug. A drug of recombinant human chorionic gonadotropin which is currently undergoing preclinical studies was also presented at the booth. In addition, the enterprise is preparing to launch the production of human gonadotropin-releasing hormone antagonist drugs—Cetrorelix and Ganirelix.
Since 2009, the Medsintez Plant has been ensuring reliable drug safety for Russian diabetics, providing the country with high-quality insulin drugs. At the booth, one could see drugs of genetically engineered human insulin Rosinsulin and analogue forms of insulins Rosinsulin Aspart R and Rosinsulin Glargine, which are produced by the enterprise from its own substances. The enterprise has developed and patented the design of disposable and reusable injection pens that ensure high precision dosing of the preparation.
In 2024, the Medsintez Plant launched the production of the substance and finished dosage forms of the recombinant human albumin drug, which is widely used in medicine. The genetically engineered drug has the same biological activity as native human albumin, but unlike it, it is free of impurities and can be produced on a large scale without contamination by pathogens. The production of recombinant human albumin does not depend on the number of donors, so there will be a demand for it (especially in the conditions of the special military operation) in Russia. The drug is available as a solution for infusion in various dosages in vials and bags of various volumes.
In addition, in 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched a full-cycle production of hypoglycemic drugs for the treatment of type 2 diabetes mellitus—Liraglutide and Semaglutide. The production of domestic glucagon-like peptide 1 (GLP-1) receptor agonists will help fill the shortage of similar drugs arisen in the country due to the cessation of supplies from foreign manufacturers.
National drug safety is a priority of the Medsintez Plant: highly qualified specialists of the enterprise are able to develop new drugs, organize production sites in the shortest possible time, equip them with high-tech equipment and ensure uninterrupted supplies of drugs to hospitals and pharmacies of the country.